Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J).

[1]  N. Miyasaka,et al.  Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study. , 2021, Rheumatology.

[2]  D. Solomon,et al.  Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat‐to‐Target Strategies , 2020, Arthritis & rheumatology.

[3]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[4]  I. Haugen,et al.  Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis , 2019, Annals of the rheumatic diseases.

[5]  E. Soriano,et al.  Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort , 2019, Clinical Rheumatology.

[6]  T. Kvien,et al.  Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study. , 2019, Seminars in arthritis and rheumatism.

[7]  T. Tomita,et al.  Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis , 2019, Modern rheumatology.

[8]  T. Mimori,et al.  Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort , 2018, International journal of rheumatic diseases.

[9]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[10]  E. Keystone,et al.  Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort. , 2014, Rheumatology.

[11]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[12]  S. Saevarsdottir,et al.  Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial , 2010, Annals of the rheumatic diseases.

[13]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[14]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[15]  D. M. van der Heijde,et al.  Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade , 2008, Annals of the rheumatic diseases.

[16]  K. Ikari,et al.  Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J) , 2008, Modern rheumatology.

[17]  M. Uffmann,et al.  Patients and Methods , 2022 .

[18]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[19]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[20]  G. Jones,et al.  The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. , 2003, Rheumatology.

[21]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.